Fennec Pharmaceuticals Inc. (FENC) is a Healthcare stock trading at $9.05 (as of 2026-06-18), with a market capitalization of $335.21M and a trailing P/E of -31.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Fennec Pharmaceuticals Inc. is a biopharmaceutical company with PEDMARK, a clinical-stage formulation of sodium thiosulfate intended to help prevent platinum-induced ototoxicity in pediatric cancer patients. The company is based in Research Triangle Park, North Carolina.